MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally...


MAP Pharmaceuticals (MAPP) says its new drug application resubmission for Levadex, an orally inhaled drug for the potential treatment of acute migraine, has been accepted for filing by the FDA. The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26 action letter and has set a goal date of April 15, 2013 under the prescription drug user fee act.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs